Treatment of spinal cord injury, traumatic brain injury, stroke and neurodegenerative disorders with a monoclonal antibody

Tech ID: 25794 / UC Case 2016-235-0


Most people who suffer traumatic spinal cord injuries have incomplete lesions of neural circuits whose function can be partially restored from the reconfiguration of the spared circuits with rehabilitative training. Methods for improving nerve regeneration after spinal cord injury or nerve transplantation are needed for improved patient outcome. Also, neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer’s Disease and Parkinson’s Disease negatively impact quality of life. 

Technology Description

UC San Diego investigators have developed a new monoclonal antibody against a portion of Ryk (part of the Wnt pathway) and a method for inhibiting degeneration of a neuron and potentially treating spinal cord injury and neurodegenerative diseases.  The Ryk antibody significantly improved the recovery of fine motor skills in rats with spinal cord injury measured by a reaching and grasping task.    


Possible commercial applications include treatment of damaged nerves, for example spinal cord injury, stroke and treatment of neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis, Alzheimer’s Disease or Parkinson’s Disease.    

State Of Development

This monoclonal antibody has been tested in animal models of spinal cord injury.

Intellectual Property Info

A patent application has been filed. This technology is available for licensing.

Related Materials

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20190119386 04/25/2019 2016-235
Patent Cooperation Treaty Published Application 2017172733 10/05/2017 2016-235


Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information


spinal cord injury, spinal trauma, neurodegenerative, TBI, Alzheimer Disease, Parkinson's Disease, ALS, stroke

Categorized As